Hello, sir. Thank you for the opportunity and congratulations on a great set of numbers. My first question is, we have not talked much about, you know, non-GLP DDC projects. I think PPT mentioned several of them. Seven, at least, were won recently, and these are high-value molecules. So, it would be great if you can, you know, provide some color on this, either, you know, therapeutic area. What would be the commercialization timelines? What would be the potential of these, you know, non-GLP DDC molecules? Can they sum up to, let's say, 10 million, 20 million in volume? If you can give some color on that, that would be really helpful.
Okay, good to hear that, sir. My next question, sir, is -- and congratulations on passing, you know, on these audits. So one clarification there now is for Brazil approval, there is no pending action on at least OneSource, right? Is that a fair assumption to make? And then similar update, can you give on Health Canada? I mean, is Health Canada inspection done or there would likely be another inspection before the product gets approved?